Semaglutide Improves Metabolic Abnormalities and Fertility in Obese Infertile Women With Polycystic Ovary Syndrome
- Status
- UnknownResults none
- Why it is watched
- non-weight indication: endocrine, other_emerging
- Who it enrolls
- age 22 Years to 40 Years; female; excludes diabetes; BMI ≥28 required; conditions: PCOS (Polycystic Ovary Syndrome); Semaglutide
- Interventions
- Metformin Hydrochloride 500 MG; Semaglutide, 1.34 mg/mL; Semaglutide, 1.34 mg/mL and Metformin Hydrochloride 500 MG; calorie-restricted diet; physical exercise
- Conditions
- PCOS (Polycystic Ovary Syndrome); Semaglutide
- Phase and size
- Phase 4 · 75 participants
- Dates
- Start 2023-05-09
Primary completion 2024-12-31 - Sponsor
- Peking University First Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Percentage change in bodyweight at 12 weeks for semaglutide versus metforminat the end of 12 weeks of treatment
- Achievement of weight reduction of at least 5% at 12 weeks for semaglutide versus metforminat the end of 12 weeks of treatment
02Eligibility
Who can take part
Inclusion Criteria: 1. Meet the PCOS diagnostic criteria (Rotterdam） 2. Age 22-40 3. BMI ≥ 28 kg/m2 4. Infertility: having normal sexual life and failing to conceive without contraception for more than 1 year 5. Willing to be pregnant, and her husband has no serious infertility Exclusion Criteria: 1. History of acute pancreatitis, individual or family history of medullary thyroid cancer and multiple endocrine adenomas 2. Type 1 diabetes and special type diabetes 3. History of tumor 4. Serious cardiovascular and cerebrovascular disease, mental disease, liver or kidney disease 5. Metformin, GLP-1 RA and other drugs affecting reproductive and metabolic functions were used within 90 days before the study 6. Known allergy to metformin, GLP-1 RA and excipients 7. Severe endometriosis, low ovarian reserve, premature ovarian failure 8. Inability to tolerate pregnancy and ovulation induction therapy 9. Other conditions considered unsuitable for this study by researchers
03Change log
Registry changes
No changes recorded since the trial was added.